Back to News
Market Impact: 0.35
Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Phathom Pharmaceuticals reported third-quarter 2026 net revenue of $84.7 million, up 71% from $49.5 million a year earlier. The company attributed the increase to continued growth in prescriptions for VOQUEZNA, its GERD treatment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PHAT0.70
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates